Trial Profile
A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Eszopiclone (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Sumitomo Pharma America
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 06 Mar 2009 Preliminary results were reported in a media release, dated 6 March 2009 [www.sepracor.com].